CG Oncology (CGON) Other financing activities (2023 - 2026)
CG Oncology's (CGON) quarterly Other financing activities came in at $1.7 million in Q1 2026, up 144.72% YoY from $682000.0 in Q1 2025, and up 154.42% on a QoQ basis from $656000.0 in Q4 2025.
CG Oncology (CGON) Other financing activities (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Other financing activities data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Other financing activities rose 144.72% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (up 991.35% YoY) and the FY2025 annual result came in at $6.5 million, down 98.41% from the prior year.
- Other financing activities improved to $1.7 million in Q1 2026, from $656000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $406.4 million in Q1 2024 to a low of $19000.0 in Q2 2025.
- A 4-year average of $41.7 million and a median of $669000.0 in 2025 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities jumped 597561.76% — and 2025, when it slumped 99.83%.
- Tracing CGON's Other financing activities over 4 years: stood at $262000.0 in 2023, then soared by 155018.32% to $406.4 million in 2024, then sank by 99.84% to $656000.0 in 2025, then surged by 154.42% to $1.7 million in 2026.
- The last three Other financing activities figures came in at $1.7 million (Q1 2026), $656000.0 (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.08 Mn |
| Jun 30, 2026 | 2.08 Mn |
| Mar 31, 2026 | 1.67 Mn |
| Mar 31, 2026 | 1.67 Mn |
| Dec 31, 2025 | 656,000.00 |
| Dec 31, 2025 | 656,000.00 |
| Sep 30, 2025 | 5.10 Mn |
| Sep 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 682,000.00 |
| Mar 31, 2025 | 682,000.00 |
| Mar 31, 2024 | 406.41 Mn |
| Mar 31, 2024 | 406.41 Mn |
| Dec 31, 2023 | 262,000.00 |
| Dec 31, 2023 | 262,000.00 |
| Sep 30, 2023 | 1.59 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 165,000.00 |